FERN: is it possible to conduct a randomised controlled trial of intervention or expectant management for early-onset selective fetal growth restriction in monochorionic twin pregnancy - protocol for a prospective multicentre mixed-methods feasibility study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khalil Asma, Prasad Smriti, Woolfall Kerry, Mitchell Tracy Karen, Kirkham Jamie J, Yaghi Odai, Ricketts Tracey, Attilakos George, Bailie Carolyn, Cornforth Christine, Denbow Mark, Hardman Louise, Harrold Jane, Parasuraman Rajeswari, Leven Shauna, Marsden Joel, Mendoza Jessica, Mousa Tommy, Nanda Surabhi, Thilaganathan Baskaran, Turner Mark, Watson Michelle, Wilding Karen, Popa Mariana, Alfirevic Zarko, Anumba Dilly, Ashcroft Richard Edmund, Baschat Ahmet, da Silva Costa Fabrício, Deprest Jan, Fenwick Natasha, Haak Monique C, Healey Andy, Hecher Kurt, Impey Lawrence, Jackson Richard J, Johnstone Edward D, Lewi Liesbeth, Lopriore Enrico, Papageorghiou Aris T, Pasupathy Dharmintra, Sandall Jane, Sharp Andrew, Thangaratinam Shakila, Vollmer Brigitte, Yinon Yoav
Аннотация
METHODS AND ANALYSIS: The FERN study is a prospective mixed-methods feasibility study. The primary objective is to recommend whether an RCT of intervention vs expectant management of sFGR in monochorionic twin pregnancy is feasible by exploring women's preference, clinician's preference, current practice and equipoise and numbers of cases. To achieve this, we propose three distinct work packages (WPs). WP1: A Prospective UK Multicentre Study, WP2A: a Qualitative Study Exploring Parents' and Clinicians' Views and WP3: a Consensus Development to Determine Feasibility of a Trial. Eligible pregnancies will be recruited to WP1 and WP2, which will run concurrently. The results of these two WPs will be used in WP3 to develop consensus on a future definitive study. The duration of the study will be 53 months, composed of 10 months of setup, 39 months of recruitment, 42 months of data collection, and 5 months of data analysis, report writing and recommendations. The pragmatic sample size for WP1 is 100 monochorionic twin pregnancies with sFGR. For WP2, interviews will be conducted until data saturation and sample variance are achieved, that is, when no new major themes are being discovered. Based on previous similar pilot studies, this is anticipated to be approximately 15-25 interviews in both the parent and clinician groups. Engagement of at least 50 UK clinicians is planned for WP3.
ETHICS AND DISSEMINATION: This study has received ethical approval from the Health Research Authority (HRA) South West-Cornwall and Plymouth Ethics Committee (REC reference 20/SW/0156, IRAS ID 286337). All participating sites will undergo site-specific approvals for assessment of capacity and capability by the HRA. The results of this study will be published in peer-reviewed journals and presented at national and international conferences. The results from the FERN project will be used to inform future studies.
TRIAL REGISTRATION NUMBER: This study is included in the ISRCTN Registry (ISRCTN16879394) and the NIHR Central Portfolio Management System (CPMS), CRN: Reproductive Health and Childbirth Specialty (UKCRN reference 47201).